IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizoti
Go back to IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizoti| (NASDAQ: IDYA) | Delayed: 31.23 -0.03 (0.1%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $31.26 | 52 Week High | $ | |||
| Open | $31.84 | 52 Week Low | $ | |||
| Day High | $32.34 | P/E | N/A | |||
| Day Low | $30.65 | EPS | $ | |||
| Volume | 2,018,518 | |||||
